Skip to main content

Table 4 Prevalence and incidence density of clusters of chronic comorbidity; before, at time of, and after diabetes diagnosis (DD)1

From: Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study

  Before diabetes Date of DD After diabetes
Disease cluster2 ID year before DD3 Prevalence at DD, % (95% CI)4 ID first year after DD3 ID first 5 years after DD3 ID first 10 years after DD3
Cardiovascular 176.9 (127.9 to 225.9) 64.0 (60.4 to 67.5) 122.3 (77.0 to 167.6) 105.5 (82.9 to 128.0) 101.0 (82.1 to 119.9)
Musculoskeletal 31.3 (15.5 to 47.1) 31.1 (27.8 to 34.6) 21.6 (8.2 to 35.0) 27.9 (20.1 to 35.8) 31.6 (24.6 to 38.6)
Mental 15.2 (4.7 to 25.8) 24.1 (21.1 to 27.3) 5.8 (0.0 to 12.4) 10.4 (5.9 to 14.8) 12.6 (8.5 to 16.7)
Eye and ear 29.6 (15.1 to 44.0) 22.7 (19.7 to 25.9) 46.9 (28.1 to 65.6) 45.3 (35.7 to 54.9) 42.8 (34.9 to 50.7)
Urogenital (male and female) 23.7 (11.3 to 36.1) 15.4 (12.9 to 18.2) 17.6 (6.7 to 28.5) 16.9 (11.5 to 22.4) 15.5 (11.2 to 19.8)
Urogenital5 26.7 (8.2 to 45.2) 13.4 (10.1 to 17.3) 14.1 (0.3 to 27.9) 12.8 (6.1 to 19.5) 14.1 (8.2 to 20.0)
Urogenital6 20.6 (4.1 to 37.0) 17.4 (13.7 to 21.5) 21.0 (4.2 to 37.8) 21.0 (12.4 to 29.6) 16.9 (10.5 to 23.2)
Respiratory 6.8 (0.1 to 13.4) 14.1 (11.7 to 16.9) 3.4 (0.0 to 8.2) 4.3 (1.6 to 6.9) 3.8 (1.7 to 5.8)
Skin 8.0 (1.0 to 15.1) 9.9 (7.9 to 12.3) 1.6 (0.0 to 4.8) 3.8 (1.3 to 6.3) 3.1 (1.3 to 5.0)
Digestive 3.2 (0.0 to 7.5) 8.5 (6.7 to 10.8) 3.2 (0.0 to 7.7) 3.7 (1.3 to 6.1) 4.0 (1.9 to 6.1)
Endocrine and metabolic 9.4 (1.9 to 17.0) 8.4 (6.5 to 10.6) 4.8 (0.0 to 10.3) 6.7 (3.4 to 9.9) 5.7 (3.2 to 8.2)
Malignancies 14.0 (4.8 to 23.1) 7.3 (5.5 to 9.4) 14.4 (5.0 to 23.7) 15.9 (10.9 to 20.9) 17.5 (13.2 to 21.9)
Neurologic 1.5 (0.0 to 4.4) 3.4 (2.2 to 4.9) 1.5 (0.0 to 4.5) 2.0 (0.2 to 3.7) 1.9 (0.5 to 3.3)
Blood and lymphatics 4.4 (0.0 to 9.3) 0.4 (0.1 to 1.1) 0.0 1.5 (0.0 to 3.0) 1.6 (0.3 to 2.8)
Infectious 0.0 0.3 (0.0 to 0.9) 0.0 0.0 0.0
  1. Abbreviations: ID, incidence density.
  2. 1Confidence intervals (CIs) for proportions were calculated with the Mid-P exact test. CIs for person time were calculated as normal approximation to the Poisson interval. Values smaller than 0.05 have been truncated to 0.0.
  3. 2Clusters: comorbid diseases were classified into clusters, after The International Classification of Primary Care (ICPC)-1 chapters. Sorted by decreasing prevalence at date of DD. The cluster 'general/unspecified' was removed because it contained only one case.
  4. 3Incidence density in a specified time period was calculated as the number of new cases of one or more diseases within a cluster of comorbidity, divided by the number of person-years at risk for a diagnosis of the particular cluster. Expressed as number of new cases per 1,000 patient-years at risk (95% CI).
  5. 4Prevalence at diabetes date was calculated as the number of patients with comorbidity in the cluster of interest at date of DD, divided by the total number of patients (n = 714).
  6. 5Prevalence and incidence density displayed only for men in the study population.
  7. 6Prevalence and incidence density displayed only for women in the study population.